PA Capital’s Palvella Therapeutics PVLA Stock Holding History

PA Capital’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-228	Closed	-$48K	–	139
2018 Q4	$48K	Buy	+228	New	+$70.7K	0.05%	110

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PA Capital's PVLA Position: Q1 2019 in Review

PA Capital sold out of Palvella Therapeutics (PVLA) in Q1 2019, closing a stake of 228 shares — an estimated $48K sold.

PA Capital first reported a position in PVLA in Q4 2018 and held it in 1 quarter. The position peaked at $48K in Q4 2018. 92 funds tracked by Wall St. Rank hold PVLA as of Q1 2019.

PA Capital reported no remaining Palvella Therapeutics position as of Q1 2019 after selling out during the quarter.
PA Capital sold 228 Palvella Therapeutics shares in Q1 2019, an estimated $48K.
PA Capital first reported a position in Palvella Therapeutics in Q4 2018 and held it in 1 quarter.
PA Capital's Palvella Therapeutics position peaked at $48K in Q4 2018.
92 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2019.

Based on PA Capital's 13F filing for Q1 2019, filed 10 May 2019.